BI gets on the right page with first AMNOG resubmission for Trajenta
This article was originally published in Scrip
Executive Summary
Boehringer Ingelheim is the first company to take a second shot at winning a favourable outcome for a product that initially fell foul of Germany's AMNOG early benefit assessment system. Thanks to new changes to the system, BI has essentially rearranged its data and resubmitted the file for its Dpp-4 inhibitor Trajenta (lintagliptin).